Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-365-5600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$49.87 million
Profitability
Miscellaneous
Employees209
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions
What is Five Prime Therapeutics' stock symbol?
Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."
How were Five Prime Therapeutics' earnings last quarter?
Five Prime Therapeutics Inc (NASDAQ:FPRX) issued its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($1.02) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.05. The biotechnology company earned $5.35 million during the quarter, compared to analyst estimates of $5.71 million. Five Prime Therapeutics had a negative return on equity of 54.87% and a negative net margin of 683.89%. View Five Prime Therapeutics' Earnings History.
When is Five Prime Therapeutics' next earnings date?
What price target have analysts set for FPRX?
7 Wall Street analysts have issued twelve-month target prices for Five Prime Therapeutics' stock. Their forecasts range from $10.00 to $44.00. On average, they expect Five Prime Therapeutics' stock price to reach $21.3333 in the next year. This suggests a possible upside of 281.6% from the stock's current price. View Analyst Price Targets for Five Prime Therapeutics.
What is the consensus analysts' recommendation for Five Prime Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Five Prime Therapeutics.
Has Five Prime Therapeutics been receiving favorable news coverage?
News coverage about FPRX stock has been trending somewhat positive on Thursday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Five Prime Therapeutics earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Five Prime Therapeutics.
Who are some of Five Prime Therapeutics' key competitors?
Some companies that are related to Five Prime Therapeutics include Arvinas (ARVN), Deciphera Pharmaceuticals (DCPH), Emisphere Technologies (EMIS), Y-mAbs Therapeutics (YMAB), Kura Oncology (KURA), CannTrust (CNTTF), Eagle Pharmaceuticals (EGRX), Omeros (OMER), Kiniksa Pharmaceuticals (KNSA), MacroGenics (MGNX), Rhythm Pharmaceuticals (RYTM), Advanz Pharma (CXRXF), DiaMedica Therapeutics (DMCAF), ZEALAND PHARMA/S (ZEAL) and Vanda Pharmaceuticals (VNDA).
What other stocks do shareholders of Five Prime Therapeutics own?
Who are Five Prime Therapeutics' key executives?
Five Prime Therapeutics' management team includes the folowing people:
- Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 50)
- Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 48)
- Dr. Helen Louise Collins, Sr. VP & Chief Medical Officer (Age 56)
- Dr. Peder K. Jensen, Advisor & Director (Age 64)
- Mr. David V. Smith, Exec. VP & CFO
Who are Five Prime Therapeutics' major shareholders?
Which institutional investors are buying Five Prime Therapeutics stock?
How do I buy shares of Five Prime Therapeutics?
Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Five Prime Therapeutics' stock price today?
One share of FPRX stock can currently be purchased for approximately $5.59.
How big of a company is Five Prime Therapeutics?
Five Prime Therapeutics has a market capitalization of $201.60 million and generates $49.87 million in revenue each year. The biotechnology company earns $-140,450,000.00 in net income (profit) each year or ($4.13) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe.View Additional Information About Five Prime Therapeutics.
What is Five Prime Therapeutics' official website?
How can I contact Five Prime Therapeutics?
Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]
MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)
| Community Ranking: | | 2.8 out of 5 ( ) |
| Outperform Votes: | | 269 (Thanks for Voting!) |
| Underperform Votes: | | 212 (Thanks for Voting!) |
| Total Votes: | | 481 |
